EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening

Xinxin Rao iD, Zhibin Qiao, Yang Yang, Yun Deng, Zhen Zhang, Xiaoli Yu, Xiaomao Guo iD

Pharmaceuticals · 08.02.2024 · 17 (2) · 225

DOI: 10.3390/ph17020225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.02.2024. Verfasst von Xinxin Rao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Key Clinical Specialty Project of Shanghai., Key Clinical Specialty Project of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) poses a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Epigenetic modifications contribute to TNBC tumorigenesis and drug resistance, offering potential therapeutic targets. Recent advancements in three-dimensional (3D) organoid cultures, enabling precise drug screening, hold immense promise for identifying novel compounds targeting TNBC. In this study, we established two patient-derived TNBC organoids and implemented a high-throughput drug screening system using these organoids and two TNBC cell lines. Screening a library of 169 epigenetic compounds, we found that organoid-based systems offer remarkable precision in drug response assessment compared to cell-based models. The top 30 compounds showing the highest drug sensitivity in the initial screening were further assessed in a secondary screen. Four compounds, panobinostat, pacritinib, TAK-901, and JIB-04, targeting histone deacetylase, JAK/STAT, histone demethylases, and aurora kinase pathways, respectively, exhibited potent anti-tumor activity in TNBC organoids, surpassing the effect of paclitaxel. Our study highlights the potential of these novel epigenetic drugs as effective therapeutic agents for TNBC and demonstrates the valuable role of patient-derived organoids in advancing drug discovery.

Schlagwörter

Stichwörter der Autor:innen

drug screeningepigenetic inhibitorspatient-derived organoidstreatmenttriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.

ORCID-Profile: Xinxin Rao, Xiaomao Guo

Förderung

  • the Key Clinical Specialty Project of Shanghai.
  • Key Clinical Specialty Project of Shanghai

Zitieren

APA

Rao, X., Qiao, Z., Yang, Y., Deng, Y., Zhang, Z., Yu, X., & Guo, X. (2024). Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening. Pharmaceuticals, 17(2), 225. https://doi.org/10.3390/ph17020225

Vancouver

Rao X, Qiao Z, Yang Y, Deng Y, Zhang Z, Yu X, et al. Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening. Pharmaceuticals. 2024;17(2):225. doi:10.3390/ph17020225

BibTeX
@article{Rao2024,
  author = {Rao, Xinxin and Qiao, Zhibin and Yang, Yang and Deng, Yun and Zhang, Zhen and Yu, Xiaoli and Guo, Xiaomao},
  title = {Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {2},
  pages = {225},
  doi = {10.3390/ph17020225}
}
Kostenlos starten →